Clinical Trial Update: Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART [Phase 2]

View source ↗

Summary

Phase 2 trial of Ampligen in HIV patients failing HAART was terminated; the document summarizes safety and efficacy observations from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ampligen (rintatolimod)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: HIV Seropositivity, HIV Infection | Phase 2 | Status: TERMINATED